Apollomics (APLM) Cash & Equivalents (2020 - 2025)

Apollomics (APLM) has reported Cash & Equivalents for 5 consecutive years, with $3.3 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Cash & Equivalents changed N/A year-over-year to $3.3 million; the TTM figure through Dec 2025 stood at $3.3 million (changed N/A YoY), while the FY2025 annual figure was $3.3 million, changed N/A from the prior year.
• Cash & Equivalents retreated to $3.3 million in Q4 2025 per APLM's latest filing, from $25.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $50.7 million in Q2 2022 and bottomed at $3.3 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $23.7 million across 4 years, with a median of $25.3 million in 2023.
• Annual changes were most pronounced in 2021 — Cash & Equivalents slumped 95.04% — and 2022, when it soared 403.78%.
• Apollomics' Cash & Equivalents stood at $6.5 million in 2021, then jumped by 403.78% to $32.7 million in 2022, then declined by 22.58% to $25.3 million in 2023, then sank by 87.05% to $3.3 million in 2025.
• Business Quant data shows APLM's Cash & Equivalents at $3.3 million in Q4 2025, $25.3 million in Q2 2023, and $32.7 million in Q4 2022.